Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Jul 12;40(1):313.
doi: 10.1007/s10103-025-04567-9.

Amber LED photobiomodulation versus tranexamic acid for the treatment of melasma: randomized controlled double-blind pilot trial

Thais Rodrigues Galache  1   2 , Marcelo Galache  2 , Renata Taylor de Brito Barros  1 , Cicero Dayves da Silva Bezerra  1 , Michelle Mota Sena  1 , Christiane Pavani  3
Affiliations
Randomized Controlled Trial

Amber LED photobiomodulation versus tranexamic acid for the treatment of melasma: randomized controlled double-blind pilot trial

Thais Rodrigues Galache et al. Lasers Med Sci. .

Abstract

Purpose: This study aimed to evaluate the efficacy of amber photobiomodulation (PBM) compared to topical tranexamic acid (TXA) for the treatment of melasma.

Methods: In a non-inferiority randomized controlled trial, 21 women were randomized to either active PBM with placebo cream (n = 10) or sham PBM with 5% liposomal TXA cream (n = 11) for 12 weeks. A noninferiority study was chosen based on the hypothesis that PBM could offer comparable efficacy to TXA with fewer adverse effects. The primary outcome was the Melasma Area and Severity Index (MASI). Secondary outcomes included corneomelametry, Physician's Global Assessment (PGA), quality of life measured by the MELASQoL questionnaire, and adverse events.

Results: No significant differences were observed in the MASI or PGA scores, within or between groups. However, the study was underpowered (51% power) due to early termination and is thus considered a pilot. A transient increase in pigmentation intensity was observed in the TXA groups at week six. Despite the lack of clinical improvement, both groups sustained improvements in quality of life. The adverse events were mild, with PBM associated with warmth and TXA with a burning sensation. The absence of MASI reduction can be attributed to the elevated environmental temperatures during the study period, consistently above historical averages. In addition, both PBM and TXA may have limited efficacy in cases of chronic or dermal melasma.

Conclusion: Although no significant clinical changes were detected in MASI or PGA, both treatments improved the quality of life, highlighting the importance of patient-reported outcomes. Given the small sample size and potential environmental confounders-particularly elevated temperatures during the study period-definitive conclusions about treatment efficacy cannot be drawn. Future studies should consider optimized protocols and/or combination therapies.

Trial registration: Clinical Trials No. NCT05326997, April 14th 2022.

Keywords: Amber; Hyperpigmentation; LLLT; Photobiomodulation; Phototherapy; Tranexamic acid.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval: The protocol was approved by the Research Ethics Committee of the Universidade Nove de Julho (UNINOVE) 5,332,384. Competing interests: The authors declare no competing interests. Patient consent statement: All participants completed the patient informed consent form. Disclosure of conflicts of interest: The authors have no disclosures. Clinical trial registration: Clinical Trials No. NCT05326997.

References

    1. Kwon S, Na J, Choi J, Park K (2019) Melasma: updates and perspectives. Exp Dermatol 28:704–708. https://doi.org/10.1111/exd.13844 - DOI - PubMed
    1. Galache TR, Sena MM, Tassinary JAF, Pavani C (2024) Photobiomodulation for melasma treatment: integrative review and state of the art. Photodermatology. Photoimmunology Photomed 40. https://doi.org/10.1111/phpp.12935
    1. Ogbechie-Godec OA, Elbuluk N (2017) Melasma: an Up-to-Date comprehensive review. Dermatol Ther (Heidelb) 7:305–318. https://doi.org/10.1007/s13555-017-0194-1 - DOI - PubMed - PMC
    1. Dias MO, Minagawa FH, Teixeira de Abreu AF et al (2024) Prevalence of facial melasma among adult women in a multiracial population. Int J Dermatol 63. https://doi.org/10.1111/ijd.17078
    1. Ocampo-Candiani J, Alas‐Carbajal R, Bonifaz‐Araujo JF et al (2025) Latin American consensus on the treatment of melasma. Int J Dermatology 64:499–512. https://doi.org/10.1111/ijd.17522 - DOI

Publication types

Associated data

LinkOut - more resources